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Abstract
As an ever-progressing field of study, vaccine development has made headway over the past decades. By doing a comparative study
between development of the measles vaccine in the mid-20th century, and the ongoing development of the COVID-19 vaccine in
2020, many of the insights and advancements in the field can be easily highlighted. First, the knowledge and experience gained over
those decades has helped the vaccine developing process become more efficient.With more vaccines in production, or at least under
study, it is more likely to have a related precedent to build upon, as opposed to relying on a successful vaccine of some unrelated
disease. More to the point, different vaccine types have altered the way researchers attempt to formulate future vaccines. No longer
are inactivated and attenuated vaccines the only option; subunit vaccines, as well as innovative, (though yet to be proven), nucleic acid
vaccines are now additional approaches.These advancements have opened doors for researchers in their quest to fight diseases.This
paper will explore the advancements and their impact on the present-day COVID-19 vaccine development.
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Advancements in Vaccine Development:
Measles vs. COVID-19
Though the majority of successful vaccines were developed in the 1900s, the challenge to develop vaccines still
exists today, with both known diseases, such as cancer,
as well as with novel infections that sweep the world.
Measles used to be a common childhood disease; one
which everyone contracted and with the majority of
patients recovering completely. It was practically inevitable until the late 1900s, when a measles vaccine was
introduced to the public. In the mid-1950s, after weeks of
trying, John Enders’s lab successfully isolated the measles
virus. Eventually, through implementation of routine measles vaccine—one dose at 12-15 months, and a second at
4-6 years—measles was successfully eradicated from the
U.S. in 2000, and from the Americas in 2016 (The College
of Physician of Philadelphia, n.d.). However, that milestone
of eliminating measles was not yet to be reached, as it was
another ten years from the isolation of the virus until the
measles vaccine officially debuted.
Contrastingly, it took Chinese researchers weeks to
sequence the genome of SARS-CoV-2, a feat way beyond
the simplicity of merely isolating the virus. Even more so,
a projected release date for a safe and effective COVID19 vaccine is only 12-18 months from the start of development, and one can only hope that the vaccine will eradicate the virus. Normally, vaccine development with FDA
approval can take anywhere from 5-10 years. Obviously,
vaccine technology has critically advanced in the decades
since the measles vaccine, thus allowing researchers to
expedite the vaccine development process for COVID19 and all future pandemics. This paper will explore some
of these advancements and their potential impact on the
COVID-19 vaccine development.
Methods
All of the information discussed in the paper was obtained through the PubMed database, as well as via
Google searches which led to government sites, like the

CDC and NIH, and also to known and established medical sciences related sites, like CHOP and The College of
Physicians of Philadelphia.
The majority of the amassed information pertained to the
techniques involved in developing both the measles vaccine
and the potential COVID-19 vaccine, so that I could compare and contrast the respective availability of resources.
One study explored in the paper included vaccine trial
studies in which the efficacy of various measles vaccines
were tested either alone, or in a series with other forms
of developing measles vaccines. At a designated interval
after each trial, measles titers were measured and eventually, the most effective vaccine was sought out.
There are currently over one hundred biotechnology
companies and universities developing vaccine candidates
for COVID-19. For the vaccine studies that are not yet
ready for human test trials, i.e. majority of the COVID-19
studies, this paper analyzed selected studies which elaborated on the numerous approaches towards an effective
COVID-19 vaccine.
Discussion
An Overview of Vaccines
How vaccines work
The purpose of a vaccine is to trigger the immune system
to stimulate an initial immune response and ultimately
create a cellular memory mechanism to fight future attacks by the pathogen. This way, when the body is exposed to the actual disease in the future, the body will
produce an immediate secondary immune response and
not a primary response (Clem, 2011). Secondary immune
responses are quicker and more specific, and are therefore better than a primary immune response.
Classically, vaccines are created by deactivating or attenuating the virulent part of the pathogen, while leaving the
antigenic portion of the pathogen intact so that the vaccine can induce an immune response without causing the
disease itself (The College of Physicians of Philadelphia,
2018).When the body detects a foreign antigen, the innate
immune system goes into action first (Clem, 2011). The
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innate system includes non-specific white blood cells (i.e.,
macrophages and natural killer cells), which can either destroy the invader or process the pathogen and present its
antigen to aid in the adaptive immune response. Both the
humoral and cell-mediated immune responses are part
of the adaptive immune response. The humoral response
consists of B-cells, which detect the foreign antigen and
then self-mutate to find the antibody that best fits the
antigen. After that is successfully accomplished, the B-cell
that is able to produce the most effective neutralizing
antibodies replicates and becomes either plasma cells,
which secrete antibodies to help fight the current infection, or it creates memory B-cells specific to that antigen,
so that upon future infection the body will have an antibody that targets and destroys the specific disease pathogens. The cell-mediated immune response contains two
types of cells, T-killer and T-helper cells, which are either
activated by major histocompatibility complex I (MHC I)
or major histocompatibility complex II (MHC II). MHC
proteins are expressed on the surface of all bodily cells
to signal that the cells belong in the body. However, when
the cells become infected with a pathogen the MHC will
take the processed antigen and present it on the surface
of the cell, so that the T cells of the cell-mediated immune
system can respond. T-killer cells recognize the antigen
presented by MHC I molecules and subsequently advance
to kill the invading cell. On the other hand, T-helper cells
recognize the antigen presented by MHC II molecules,
and T-helper cells aid in the activation of B cells as well
as T-killer cells. Regardless of their function, either T cell
can replicate and form T-memory cells in preparation of
future infections (Clem, 2011). In all, the job of a vaccine is
to prime the body for a future encounter with a specific
pathogenic agent.
Stages of Vaccine Production
Before any vaccine can be mass produced for public use,
it must go through a series of developmental phases to
assess first and foremost its safety, in addition to the vaccine’s efficacy, required dosage and dose frequency, and
screenings for any harmful side effects (The College of
Physicians of Philadelphia, 2018). Prior to these phases
though, researchers study the specific disease and attempt to identify its immunogenic parts. Once that has
been done, researchers can either isolate the antigenic
portion, or inactivate the virulent part, depending on
what type of vaccine they propose to create.
Following those preliminary steps, the candidate vaccine
can then enter the preclinical phase of study. In this stage,
researchers test the vaccine safety and immunogenicity
on animals (The College of Physicians of Philadelphia,
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2018). Also during this preclinical stage, researchers may
conduct what are known as challenge trials. In these tests,
researchers inject their candidate vaccine into the lab animals or human volunteers, wait an amount of time so
that the vaccine can elicit an immune response and create
memory cells, and then finally, they inject the targeted
virus into the subjects to determine if the vaccine can
do its job. Based on the challenge trial results, researchers will adjust their vaccine development accordingly.
During this phase, there may be a bit of trial and error
in determining a safe starting dose, i.e. how many viral
particles are needed to elicit an immune reaction, and
method of delivery for human subjects of the next phase
(The College of Physicians of Philadelphia, 2018). For the
COVID-19 mRNA vaccine trials conducted by Moderna
and the NIAID, three trial groups have been set up each
with a different dosage. One group is testing the low
dose of 25mcg, a second group is receiving the midrage
amount of 100mcg, and the third group is receiving the
highest dose, 250mcg (National Institute for Allergy and
Infectious Disease [NIAID], 2020).
In order to advance from the preclinical stage to the
clinical phases, the research group must submit an investigational new drug (IND) application to the FDA for approval to further their studies (The College of Physicians
of Philadelphia, 2018). Once the researchers receive
authorization, they can proceed to phase I clinical trials.
At this juncture, researchers experiment with human
subjects once again to test safety and immunogenicity
of the proposed vaccine. This step starts with healthy
adult subjects and if the vaccine is intended for younger
or older age groups, the trials gradually trend towards
the desired group. During this phase, researchers may
conduct human challenge trials as well (The College of
Physicians of Philadelphia, 2018). With regard to COVID19, Moderna has reported that after two doses of their
potential mRNA COVID-19 vaccine, participants in the
low and mid groups have expressed immunity at or above
the level in which someone who was naturally infected
would have.This seems to be a promising result for phase
I trials, especially since it seems that once someone contracts COVID-19 they do not get it again, and so the natural amount of antibodies should be sufficient for vaccine
induced protection (CBS News, 2020).
After successful phase I trials, the vaccine can move on
to phase II clinical trials. Here, researchers study a larger
test group including a control group and the main point
of this phase is to further characterize dosage, frequency
of immunization, and method of delivery (The College of
Physicians of Philadelphia, 2018). In this phase, the clinical
studies will also ascertain whether the vaccine shows any
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efficacy. Safety of the vaccine is monitored as well.
Next, there are phase III clinical trials. This is where
the potential vaccine is determined to be effective by
recruiting hundreds or thousands of volunteers to help
quantitate how effective the vaccine is in a large cohort
(The College of Physicians of Philadelphia, 2018). The
large subject group also allows for the detection of rare
side effects. During this phase, vaccine safety and dosage
are still monitored for necessary corrections. Vaccines
are never 100% effective. Measle vaccine is thought to be
about 85% effective.Therefore, phase III trials must assess
vaccine effectiveness.
Finally, after the vaccine has successfully passed through
all phases of clinical testing, the researchers can submit
a biologics license application to the FDA for licensure
of their candidate vaccine (The College of Physicians of
Philadelphia, 2018). If the FDA approves, and the CDC
subsequently recommends this vaccine for routine administration, the researchers will be able to manufacture
their vaccine and enable mass population immunization.
At this point, researchers can conduct an optional phase
IV clinical trial to further monitor the vaccine’s safety and
efficacy (The College of Physicians of Philadelphia, 2018).
Studies can also be done to learn if the vaccine has potential for any alternate uses (i.e. other than for protection of
the targeted pathogen).
Post licensure, the FDA and CDC continue to monitor
the vaccine (The College of Physicians of Philadelphia,
2018). In 1990, the FDA and CDC established the vaccine adverse event reporting system (VAERS). The VAERS
allows for anyone to report adverse side effects, which
seem to be caused by a particular vaccine.The CDC then
analyzes all of the input data to determine several conclusions. Among those conclusions are whether a new
adverse side effect has indeed been detected, and whether certain health conditions place a patient at a greater
risk of developing an adverse side effect. Also in 1990, the
CDC established the vaccine safety datalink (VSD). This
system provides access to numerous databases listing
which vaccines were given to a particular patient on the
reported date. The VSD conducts vaccine safety studies
based on questions raised in medical literature or reports
from the VAERS. In addition, the VSD monitors the safety
of new vaccines.
Advances in Vaccine Development
In the sixty years since the development of the measles
vaccine, the technologies used have improved as well as
increased. For example, while Enders, Hilleman, and all the
other researchers of that time were experimenting with
either inactivated (dead virus) or live-attenuated vaccines,

researchers of today can work with a greater variety of
vaccine types ranging from pathogen subunit vaccines
to nucleic acid vaccines (NIAID, n.d.). Both forms of the
newer vaccine methods aim at inoculating with only the
antigenic portion of the microbe as opposed to injecting
the whole pathogen, which is what is done with inactivated and attenuated vaccines. In an inactivated vaccine, the
entire pathogen is killed and then subsequently administered to the patient (Clem, 2011).Attenuated vaccines, on
the other hand, leave the pathogen partially alive, and then
upon administration, induce a stronger immune response
than inactivated vaccines. However, because the attenuated vaccine is slightly live, it does present a greater risk to
the immunocompromised community (Clem, 2011). The
challenge in designing inactivated viruses or attenuated
viral particles is that there is no set formula for how to
kill or attenuate the virus. Each virus is different. That is
why it can take months, or even years, to generate an
effective candidate vaccine.
Over the past decade, new innovative technologies
have been instituted to develop effective vaccines. Subunit
vaccines are one example where a mere pathogenic
unit—a protein, or sugars on the microbe’s outer coat—
are administered into the patient to elicit an antibody response, thus allowing a person to attain immunity (NIAID,
n.d.). However, subunits vaccines are often not effective
enough on their own and require an adjuvant to enhance
their immune response (NIAID, n.d.). While historically
composed of only aluminum salts, adjuvants today come
in many more varieties like MF59 (oil in water emulsion
composed of scalene), CpG 1018 (cytosine phosphoguanine, a synthetic form of DNA that mimics bacterial and
viral genetic material), and others (Centers for Disease
Control and Prevention [CDC], n.d.-a). All of these adjuvants serve to aid in the immunogenicity of the vaccine,
hopefully providing a stronger response and longer lasting
protection. The inclusion of adjuvants in vaccine formulation requires researchers to carefully assess where these
added compounds elicit unwanted side effects.
Contrary to the aforementioned vaccines, nucleic acid
vaccines do not inject any physical part of the pathogen
into the body. Rather, these vaccines inject a lab synthesized DNA or mRNA sequence that codes for one or
more antigenic proteins (NIAID, n.d.). Once inside the
body, the nucleic acid is taken up by the virally targeted
cells and instructs those cells to synthesize and secrete
the desired protein. Only then, after the protein is in the
body, will the body generate an immune response and
acquire antibodies to that specific disease (NIAID, n.d.).
With this method of inoculation, the body itself is an integral part in creating the immunogenic portion of the
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vaccine. An mRNA strand alone will do nothing. However,
when acted upon in vivo, the body completes the last step
in the vaccine synthesis, creating the protein to which it
needs to attain immunity.
Nucleic acid vaccines have a quicker production time
than traditional whole-pathogen vaccines (NIAID, n.d.).
This is because a pathogenic specimen does not need to
be grown for the creation of the vaccine (Park, 2020).
Under normal circumstances, the microbe can take a few
months to grow to the desired quantity.Thus, nucleic acid
vaccines may be favored over whole-pathogen vaccines,
especially in situations where time is a consideration.
Additionally, though nucleic acid vaccines can be injected directly into the body, another vaccine delivery mode
has developed over the years. Instead of injecting the
DNA or mRNA directly into the body, options now exist
to use a vector for introduction of the vaccine (NIAID,
n.d.). A vector is a small particle that acts as a vehicle for
vaccine delivery. A viral vector, such as adeno-associated
virus, can incorporate the vaccine’s genetic material by
replacing some of its viral genes with the vaccine’s desired
sequence (Robert-Guroff, 2007). Studies have proven
that viral vector administration is both safe and effective,
though the quantitative values vary amongst the viruses
(Robert-Guroff, 2007). There are also non-viral vectors,
for example, liposomes and lipid nanoparticles (LNP),
which can be used to deliver nucleic acid vaccines as well.
One advantage of non-viral vectors, is that they are less
immunogenic than their viral counterparts. With both
forms of vectors, however, the target site in the body can
be specified with the help of specific receptor molecules.
Like this, researchers can guide and control the vector’s
integration and vaccine delivery within the body.
The Measles Vaccine
In 1954, just a year before the introduction of the inactivated polio vaccine, Thomas Peebles, MD, working
in John Enders’s lab at Boston Children’s Hospital, succeeded in isolating the measles virus from the blood of
13-year-old David Edmonston (The College of Physicians
of Philadelphia, n.d.). After isolating the virus, Enders’s goal
was to formulate a vaccine. It took until 1960 to prove
that the isolated strain could be formulated into an effective attenuated measles vaccine; it just needed additional tweaking to attenuate it further (Hendriks & Blume,
2013). Wanting other researchers to also attempt to
create a measles vaccine, Enders shared the Edmonston
strain. Most researchers of that time were inspired by the
recent success of the polio vaccine, and tried to mimic
that development in their construction of a measles vaccine (Hendriks & Blume, 2013). In countries where Salk’s
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inactivated polio vaccine (IPV) took credit for controlling
the disease, like in Sweden and Netherlands, researchers
worked at creating an effective inactivated measles vaccine. In other countries, such as the U.S. and U.K., where
Sabin’s recently released oral polio vaccine (OPV) was
used to combat polio, researchers preferred to attempt
an attenuated version of the measles vaccine.
Regardless of the method chosen, subsequent patient
trials proved the attenuated measles vaccine to be more
effective than the inactive vaccine (Hendriks & Blume,
2013). Some studies created several groups, each receiving
a different vaccine regimen.While one group received only
inactivated doses, another group received some inactive
doses followed by a live dose, while a third group received
one dose of the attenuated vaccine.Though several studies
tried this method, all pointed to the same results: the inactivated vaccine initiated a lesser immune response and it
was not known how long those antibody titers would last.
The attenuated vaccine however, generated a substantial
response, making it the vaccine of choice for elimination of
measles (Hendriks & Blume, 2013).
It was in 1963 that John Enders and his associates received FDA licensure for their live-attenuated measles
vaccine and mass measles vaccination began (CDC, n.d.-b).
However, the vaccine was not attenuated enough and thus
required coadministration of gamma globulins to prevent
children from developing fever and a rash following inoculation (Hendriks & Blume, 2013). Approximately five years
later, in 1968, Maurice Hilleman, working at Merck labs,
developed Moraten—more attenuated Enders—which
eliminated the need to inject the vaccine along with
gamma globulins (Hendriks & Blume, 2013). Since licensure, Moraten, a descendant of the original Edmonston
strain, has been the only measles vaccine administered in
the U.S. (The College of Physicians of Philadelphia, n.d.).
Even today, when the monovalent vaccine is no longer on
the market, the Edmonston strain is still used to create
the measles component of the MMR vaccine routinely
given to children (CDC, n.d.-c; The College of Physicians
of Philadelphia, n.d.).
Potential COVID-19 Vaccines
The COVID-19 pandemic, rampant now in early 2020, and
possibly beyond, has killed hundreds of thousands worldwide in a matter of months (World Health Organization
[WHO], 2020a). As of June 1, 2020, the WHO reports
that there have been 371,166 deaths globally. Researchers
all over the world are racing to develop a vaccine to combat the virus and stop the ever-rising death toll.
Luckily, there is an extensive history of vaccine development, allowing researchers to base their COVID-19
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vaccine developments on the experiences and accumulated information from the past. More so, unlike the
measles vaccine development, COVID-19 vaccine development has a related precedent. Coronaviruses SARS
(severe acute respiratory syndrome) and MERS (Middle
East respiratory syndrome), while claiming no marketed
vaccine, have documented research and experimentation
on vaccine development. Current researchers are using
these semi-constructed vaccines and adapting them for
further development towards the current strain of coronavirus, SARS-CoV-2. However, regardless of the starting
inspiration, all potential COVID-19 vaccines will have to
go through all phases of vaccine production before being
offered on the market.
As of June 15, 2020, there are scores of COVID-19
vaccine candidates starting the preclinical stage or clinical
studies phase of vaccine development. These attempts
include vaccine designs containing mRNA, DNA plasmid,
protein subunit, non-replicating viral vectors, or inactivated COVID-19 viral particles (WHO, 2020b). Just the
breadth of these alone shows how many more resources and technologies are available now versus the 1960s,
when the measles vaccine was in development.
The more recent vaccine technologies, namely nucleic
acid vaccines, demonstrates how the updated and increased methods are truly playing a role in COVID-19
vaccine development. In this paper, I would like to highlight one specific mRNA candidate vaccine. (An LNPencapsulated mRNA vaccine, co-developed by Moderna
and the NIAID.) As an RNA virus with RNA-dependent
RNA polymerase, SARS-CoV-2 replicates RNA from an
RNA template as opposed to transcribing RNA from
a DNA template (using DNA-dependent RNA polymerase). This can result in high levels of RNA present
within the virus (Wang, et al., 2020). Thus, using RNA
as a method of priming the body towards an RNA-rich
pathogen makes sense in the overall picture of vaccine
development (Wang, et al., 2020).
Also, when developing this RNA vaccine, researchers
opted to use the spike protein as the vaccine’s target
sequence. Though there are other targetable proteins
on SARS-CoV-2, such as the envelope, nucleocapsid, and
membrane proteins, the spike (S) protein is the subunit
of the virus that binds with the body’s ACE2 (angiotensin converting enzyme 2) receptor, and therefore the S
protein comes across as a more effective vaccine target
(Wang, et al., 2020; Zhang, et al., 2020). Figure 1 shows
the location of all four proteins on the virus as well as the
binding of the spike protein to the ACE2 receptor.
After injection of the vaccine which contains the mRNA
sequence for the S protein, a cell in the body should

Figure 1 Proteins and Binding Site of SARS-CoV-2 Source. Zhang, et al., 2020

translate the genetic code into the functional S protein that
can be secreted to allow the immune system to respond.
Figure 2 depicts the process by which this COVID-19
mRNA vaccine ultimately yields memory cells in the body.
As of May 30, 2020, this candidate vaccine has advanced
to phase 2 clinical trials (WHO, 2020b). Though mRNA
vaccines have great theoretical potential, there are currently none on the market. However, this mRNA vaccine may
successfully proceed through all phases of vaccine development, and should that happen, the Moderna/NIAID mRNA
vaccine will be the first of its kind on the market

Figure 2 COVID-19 mRNA Vaccine Response

Conclusion
For the ongoing developments for a COVID-19 vaccine,
it is unknown whether the vaccine’s immunity will be lifelong. Currently, it is unknown if natural immunity is long
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lasting, though whatever that case is, I would hypothesize
that the artificially induced immunity would follow suit. In
my opinion, though vaccine type does play a role in duration of immunity (as illustrated in measles vaccine development), a larger portion depends upon the properties
of the virus itself. Since that is yet to be determined, it
is too soon to draw a conclusion with regards to any
COVID-19 vaccine. Also, because all vaccines are at most
in early phase II clinical trials, one cannot determine
which candidate vaccine will be more effective than the
others. Currently, the mRNA vaccine from Moderna is on
a road to success, though results are still too incipient to
make a final decision.
Finally, although the essence of a vaccine is unchanged—
the goal to elicit an effective immune response still drives
development—advancements in vaccines development
as well as accumulation of scientific knowledge have
broadened our minds when attempting to develop a new
vaccine. We now have more options, some of them with
more precise targeting than ever, and it is the hope that
with our newfound tools, we can go on to create better
vaccines and continue saving lives.
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